This approach provides information on tumor immune responses across focal areas, treatment stages, and tumor progression directly by monitoring immune biomarkers such as CTLA-4, PD-1/L1, HER2, and MHC molecules [146, 147]. This evidence concerns the gene CTLA4 and neoplasm.